Rosuvastatin in Preventing Myonecrosis in Elective Percutaneous Coronary Interventions (PCIs)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It plans to enroll 160 participants.

Also called NCT01007279

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 160 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT01007279
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Italy (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01007279. Randomized; no masking; primary purpose treatment. Start 2010-03 (registry gives no type); primary completion 2010-09 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Rosuvastatin in Preventing Myonecrosis in Elective Percutaneous Coronary Interventions (PCIs)
Acronym
ROMA
Condition
Periprocedural Myocardial Necrosis
Intervention (Drug)
ROSUVASTATIN
Lead sponsor
University of Roma La Sapienza (class: other)

Record details

Record id
cardio:ct-nct01007279
Content hash
51ba67ab995f20f3cc0a4bff815f1ed0498c025b727673c1454a9c8ad6913d26